Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: Comparison of two different Epstein-Barr virus-based vectors

Human Gene Therapy

Volumn 9, Issue 8, 1998, Pages 1131-1141

  Kenney, Shannon ^a,b   Ge, J I Qian ^a   Westphal, Eva M ^a   Olsen, John ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE;

ARTICLE; B CELL LYMPHOMA; CELL KILLING; CLONING VECTOR; EPISOME; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE THERAPY; IMMUNE DEFICIENCY; LYMPHOBLASTOID CELL LINE; VIRUS GENOME;

HUMAN HERPESVIRUS 4;

EID: 0032550754     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.8-1131     Document Type: Article

References (10)

1. AUSTIN, H.A., and HUBER, B.E. (1993). A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43, 380-387.
2. BANERJEE, S., LIVANOS, E., and VOS, J.-M. (1995). Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nature Med. 1, 1303-1308.
3. BLAESE, M., BLANKENSTEIN, T., BRENNER, M., COHEN-HAGUENAUER, O., GANSBACHER, B., RUSSELL, S., SORRENTINO, B., and VELU, T. (1995). Vectors in cancer therapy: How will they deliver? Cancer Gene Ther. 2, 291-297.
4. CHEVALLIER-GRECO, A., MANET, E., CHAVRIER, P., MOSNSIER, C., DAILLIE, J., and SERGEANT, A. (1986). Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J. 5, 3243-3249.
5. CONNERS, T.A. (1995). The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702-709.
6. COUNTRYMAN, J., and MILLER, G. (1985). Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U.S.A. 82, 4085-1089.
7. FIXMAN, E. HAYWARD, G., and HAYWARD, S.D. (1992). trans-Acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66, 5030-5039.
8. FRAEFEL, C., SONG, S., LANG, P., YU, L., WANG, Y., WILD, P., and GELLER, A. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70, 7190-7197.
9. ZHANG, Q., HONG, Y., DORSKY, D., HOLLEY-GUTHRIE, E., ZALANI, S., ALY ELSHIEKH, N., KIEHL, A., LE, T., and KENNEY, S. (1996). Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J. Virol. 70, 5131-5142.
10. ZIMMERMANN, J., and HAMMERSCHMIDT, W. (1995). Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA. J. Virol. 69, 3147-3155.